Glenmark Life Sciences Ltd
Glenmark Life Sciences, a subsidiary of Glenmark Pharmaceuticals Ltd, is one of the leading developers and manufacturers of select high-value Active Pharmaceutical Ingredients. The company further operates in Contract Development and manufacturing operations to offer services to specialty Pharmaceutical companies.[1]
- Market Cap ₹ 14,434 Cr.
- Current Price ₹ 1,178
- High / Low ₹ 1,335 / 609
- Stock P/E 32.3
- Book Value ₹ 190
- Dividend Yield 1.91 %
- ROCE 28.1 %
- ROE 21.1 %
- Face Value ₹ 2.00
Pros
- Company is almost debt free.
- Company has a good return on equity (ROE) track record: 3 Years ROE 23.7%
- Company has been maintaining a healthy dividend payout of 76.8%
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|
0 | 886 | 1,537 | 1,885 | 2,123 | 2,161 | 2,283 | 2,293 | |
0 | 638 | 1,064 | 1,294 | 1,506 | 1,518 | 1,608 | 1,653 | |
Operating Profit | -0 | 248 | 473 | 592 | 617 | 643 | 675 | 641 |
OPM % | -4% | 28% | 31% | 31% | 29% | 30% | 30% | 28% |
0 | -0 | 11 | 0 | 14 | 28 | 11 | 16 | |
Interest | 0 | 1 | 34 | 88 | 28 | 1 | 2 | 2 |
Depreciation | 0 | 19 | 29 | 33 | 38 | 42 | 53 | 55 |
Profit before tax | -0 | 228 | 421 | 471 | 565 | 629 | 631 | 600 |
Tax % | 4,200% | 14% | 26% | 25% | 26% | 26% | 25% | |
-0 | 196 | 313 | 352 | 419 | 467 | 471 | 447 | |
EPS in Rs | -430.00 | 997.86 | 1,597.37 | 358.74 | 34.17 | 38.11 | 38.43 | 36.47 |
Dividend Payout % | 0% | 0% | 0% | 0% | 61% | 110% | 59% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | 21% |
3 Years: | 7% |
TTM: | 2% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | 19% |
3 Years: | 10% |
TTM: | -9% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 21% |
1 Year: | 81% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | 31% |
3 Years: | 24% |
Last Year: | 21% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|
Equity Capital | 0 | 2 | 2 | 2 | 25 | 25 | 25 |
Reserves | -1 | 86 | 400 | 751 | 2,030 | 2,114 | 2,308 |
0 | 0 | 0 | 0 | 3 | 19 | 17 | |
1 | 1,387 | 1,324 | 1,244 | 414 | 545 | 501 | |
Total Liabilities | 0 | 1,475 | 1,726 | 1,997 | 2,471 | 2,702 | 2,850 |
0 | 456 | 546 | 573 | 590 | 781 | 805 | |
CWIP | 0 | 80 | 11 | 14 | 97 | 62 | 106 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
0 | 939 | 1,169 | 1,410 | 1,784 | 1,860 | 1,939 | |
Total Assets | 0 | 1,475 | 1,726 | 1,997 | 2,471 | 2,702 | 2,850 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|
-0 | 10 | 195 | 388 | 598 | 306 | 414 | |
0 | -9 | -51 | -69 | -122 | -147 | -116 | |
0 | 1 | -137 | -214 | -79 | -388 | -279 | |
Net Cash Flow | 0 | 2 | 8 | 106 | 397 | -228 | 18 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|
Debtor Days | 44 | 185 | 152 | 120 | 116 | 136 | 122 |
Inventory Days | 162 | 441 | 227 | 214 | 185 | 224 | 251 |
Days Payable | 41 | 201 | 111 | 92 | 110 | 158 | 139 |
Cash Conversion Cycle | 165 | 424 | 268 | 241 | 190 | 202 | 235 |
Working Capital Days | -2,059 | -186 | -37 | 12 | 150 | 177 | 188 |
ROCE % | 529% | 186% | 97% | 42% | 30% | 28% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Change of Company Name
2d - Company name changed to Alivus Life Sciences Limited.
-
Disclosure Under Regulation 30 Of The SEBI (LODR) Regulations, 2015, As Amended ('SEBI Listing Regulations')
3 Oct - Disclosure of Income Tax Intimation received.
- Shareholder Meeting / Postal Ballot-Outcome of AGM 25 Sep
- Shareholder Meeting / Postal Ballot-Scrutinizer''s Report 25 Sep
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
16 Sep - Regarding Schedule of Analyst/ Investors Meet.
Annual reports
Concalls
-
Aug 2024Transcript PPT REC
-
May 2024Transcript PPT
-
Mar 2024TranscriptNotesPPT
-
Jan 2024Transcript PPT
-
Oct 2023Transcript PPT
-
Jul 2023Transcript PPT REC
-
May 2023Transcript PPT
-
Feb 2023Transcript PPT
-
Nov 2022TranscriptNotesPPT
-
Nov 2022Transcript PPT
-
Oct 2022TranscriptNotesPPT
-
Aug 2022TranscriptNotesPPT
-
Apr 2022TranscriptNotesPPT
-
Feb 2022TranscriptNotesPPT
-
Nov 2021TranscriptNotesPPT
History
Prior to 2019 API business was an integral part of Glenmark Pharma (GPL). It was separated out of GPL into GLS through a Business Transfer Agreement in Jan 2019. GLS was listed on NSE & BSE in FY22. [1]